11 August 2025 in JACC: Cardiovascular Interventions
28 July 2025 in JACC: Cardiovascular Interventions
In patients with a cardiac implantable electronic device (CIED) using a transvenous right ventricular (RV) lead, transcatheter tricuspid valve replacement (TTVR) results in RV lead entrapment. The authors sought to evaluate outcomes of patients with pre-existing transvenous RV leads undergoing EVOQUE TTVR. Patients with a CIED referred for TTVR at 3 centers were evaluated preoperatively by the heart team. Lead and clinical assessments were performed at baseline and in follow-up per local clinical practice. The primary outcome was the nature and incidence of major lead-related complications after TTVR. Secondary outcomes included changes in lead parameters after entrapment. Of 146 EVOQUE TTVR, 52 consecutive patients with entrapped RV leads (age 81 [77-85] years; 33 female patients (63.5%), lead dwell time 8.9 [3.3-13.6] years) were evaluated. Paravalvular leak was mild or less in 47 of 48 patients (98%) 30 days post-TTVR. Four patients had procedure-related lead complications: 1 intraprocedural RV lead dislodgement; 2 implantable cardioverter-defibrillator lead fractures 6- and 8-weeks post-TTVR; and 1 methicillin-resistant Staphylococcus aureus endocarditis 1 month post-TTVR. Among 46 complication-free patients with follow-up >30 days (356 [196-965] days), there were no other lead-related adverse events. Of the 33 patients without complications who had ≥1 CIED interrogation >30 days (424 [182-1,006] days) following TTVR, there was a significant decrease in lead impedance and increase in capture threshold on the final lead assessment, but no additional patients required lead revision. Following TTVR, most with entrapped RV leads remain free of lead-related complications. The need for urgent CIED revision due to RV lead dislodgment or failure is uncommon but may occur.
24 June 2024 in JACC: Cardiovascular Interventions
A novel echocardiography-based definition of atrial functional tricuspid regurgitation (A-FTR) has shown superior outcomes in patients undergoing conservative treatment or tricuspid valve transcatheter edge-to-edge repair. Its prognostic significance for transcatheter tricuspid valve annuloplasty (TTVA) outcomes is unknown. This study sought to investigate prognostic, clinical, and technical implications of A-FTR phenotype in patients undergoing TTVA. This multicenter study investigated clinical and echocardiographic outcomes up to 1 year in 165 consecutive patients who underwent TTVA for A-FTR (characterized by the absence of tricuspid valve tenting, midventricular right ventricular [RV] dilatation, and impaired left ventricular ejection fraction) and nonatrial functional tricuspid regurgitation (NA-FTR). A total of 62 A-FTR and 103 NA-FTR patients were identified, with the latter exhibiting more pronounced RV remodeling. Compared to baseline, the tricuspid regurgitation (TR) grade at discharge was significantly reduced (P < 0.001 for both subtypes), and TR ≤II was achieved more frequently in A-FTR (85.2% vs 60.8%; P = 0.001). Baseline TR grade and A-FTR phenotype were independently associated with TR ≤II at discharge and 30 days. In multivariate analyses, A-FTR phenotype was a strong predictor (OR: 5.8; 95% CI: 2.1-16.1; P < 0.001) of TR ≤II at 30 days. At 1 year, functional class had significantly improved compared to baseline (both P < 0.001). One-year mortality was lower in A-FTR (6.5% vs 23.8%; P = 0.011) without significant differences in heart failure hospitalizations (13.3% vs 22.7%; P = 0.188). Direct TTVA effectively reduces TR in both A-FTR, which is a strong and independent predictor of achieving TR ≤II, and NA-FTR. Even though NA-FTR showed more RV remodeling at baseline, both phenotypes experienced similar symptomatic improvement, emphasizing the benefit of TTVA even in advanced disease stages. Additionally, phenotyping was of prognostic relevance in patients undergoing TTVA.
8 December 2025 in JACC: Cardiovascular Interventions
Transcatheter tricuspid valve annuloplasty (TTVA) with the Cardioband has proved to be safe and effective in acutely reducing tricuspid regurgitation (TR). However, long-term outcomes, especially regarding right heart remodeling (RHR), are scarce. The aim of this study was to assess long-term efficacy as well as RHR following TTVA. This retrospective, multicenter study included consecutive patients undergoing TTVA for severe TR at 2 German high-volume centers from 2019 to 2023. Right atrial and right ventricular (RV) parameters and NYHA functional class were assessed at baseline and follow-up. A total of 156 patients were included, and the median time to follow-up was 435 days (Q1-Q3: 156-704 days). TR reduction to ≤2+ was observed in 71% and NYHA functional class improved to ≤II in 68% (P < 0.001 for both). Compared with baseline, right atrial area (36.0 ± 10.1 cm2 vs 30.4 ± 10.7 cm2), RV length (67.5 ± 9.4 mm vs 63.7 ± 9.1 mm), RV midventricular dimension (42.6 ± 8.6 mm vs 35.6 ± 7.8 mm), and RV basal dimension (47.8 ± 6.8 mm vs 42.6 ± 7.5 mm)were significantly reduced at follow-up (P < 0.001 for all). Notably, torrential to severe TR reduction still yielded remodeling (RV basal diameter 50 ± 8.1 mm vs 44 ± 8 mm; P = 0.007). RHR was associated with a decrease in vena contracta width (OR: 1.14; 95% CI: 1.03-1.30; P = 0.015). TTVA is associated with a significant and sustained reduction of TR for more than 1 year. Additionally, patients demonstrated distinct positive cardiac remodeling and functional improvement.
5 June 2024 in JACC: Cardiovascular Interventions
1 September 2025 in Circulation: Cardiovascular Interventions
BACKGROUND: Transcatheter tricuspid valve annuloplasty (TTVA) with the Cardioband system is a safe and effective option for high-risk patients with symptomatic severe tricuspid regurgitation (TR). Hemodynamics play a crucial role in these patients. However, it remains unclear if hemodynamic changes after TTVA are linked to clinical outcomes. METHODS: Consecutive patients with severe functional TR who underwent TTVA between 2019 and 2022 were retrospectively analyzed. Right heart catheterization was performed before and after cinching to assess hemodynamic parameters, including XV height (difference between the V-wave and the nadir of right atrial pressure). The primary end point was 2-year survival. RESULTS: Fifty-eight patients with complete hemodynamic assessment were included. All patients presented with torrential (40%), severe (38%), or massive (22%) TR. TR was reduced by ≥2 grades in 83% and by ≥1 grade in 97%. Hemodynamics following TTVA showed significant increases in median cardiac index (2.4–2.8 L/[min·m²]), pulmonary artery pulsatility index (1.73–2.13), and right ventricle cardiac power index (0.15–0.21 W/m²). Right atrial pressure (mean/V-wave) decreased significantly, with the most notable change in XV height (12.5 to 7 mm Hg; P <0.001). Lower postprocedural XV height independently predicted 2-year survival ( P =0.002) and was significantly associated with lower TR grade at follow-up ( P =0.002) and right ventricle reverse remodeling ( P <0.001). Immediate right ventricle remodeling was also associated with 2-year survival ( P =0.024). CONCLUSIONS: Postprocedural XV height was independently associated with 2-year survival and linked to TR reduction and right ventricle remodeling. TTVA improves hemodynamics even in advanced TR, and hemodynamic markers may support risk stratification.